examining 3,4-methylenedioxymethamphetamine (mdma) effects on psychological, relational and hyperarousal-related neural reactivity mechanisms in veterans with ptsd and moral injury

Conditions: PTSD, Post Traumatic Stress Disorder; Moral Injury

Summary: despite being exposed to a high level of potentially traumatic experiences due to exposure to combat, military veterans have poor response rates to traditional ptsd treatments, in some reports, just 1/3 of veterans recover using traditional treatments. in recent years 3,4-methylenedioxymethamphetamine (mdma), a psychedelic drug has demonstrated a significant treatment potential for severe and treatment resistant ptsd though not specifically in a veteran population. additionally, even in groups where participants receive a placebo, the effect of the psychedelic treatment formulation, intensive, focused and respectful structure, appears to have promising effects. indeed, in the current psychedelic literature, the setting and mind with which participant approach psychedelic therapy, significantly contributes to the treatment effect. the current study proposes to address the major gaps in the theoretical literature by examining the proposed mechanisms by which mdma enhances the "window of tolerance" for ptsd therapy, specifically in those with comorbid symptoms of moral injury; namely by reducing hyperarousal and enhancing connection (to self and others) and whether mdma assisted therapy is more successful in reducing ptsd in veterans compared to a matched somatic experiential ptsd treatment, somatic experiental acceptance intensive trauma-based therapy, (sea-it) which builds upon the promising placebo results, enhancing them with somatic and acceptance based treatment protocols.

despite being exposed to a high level of potentially traumatic experiences due to exposure to combat, military veterans have poor response rates to traditional ptsd treatments. in recent years 3,4-methylenedioxymethamphetamine (mdma) has demonstrated a significant treatment potential for severe and treatment resistant ptsd though not specifically in a veteran population. the current study proposes to address the major gaps in the theoretical literature by examining the proposed mechanisms by which mdma assisted therapy (mdma-at) enhances the "window of tolerance" for ptsd therapy, specifically in those with comorbid symptoms of moral injury; namely by reducing hyperarousal and enhancing connection (to self and others) and whether mdma-at is more successful in reducing ptsd in veterans compared to a matched somatic experiential ptsd treatment (sea-it). sixty male veterans suffering from military-related ptsd, who have participated in at least one attempt at treatment previously, will be randomly assigned (non-blinded) to receive mdma-at or somatic-based therapy. all participants will undergo 3 preparation sessions and then three long (8hour) sessions each followed by 3 integration sessions. hyperarousal will be studied using eeg (electroencephalogram) to detect significant changes in event-related neural responses and cortisol responsivity to treatment. additionally measures of ptsd symptoms of hyperarousal and a specific measure of emotion regulation abilities will be studied. connection will be studied as both mediated by oxytocin responsivity to treatment and as subjective outcome measures of treatment response namely using psychological measures of connection to others and self via interoceptive sensitivity. it is predicted that by using longitudinal modeling and specifically the analysis of mediators of treatment response, the current study will enable both the understanding of the promising effects of mdma treatment and the refinement of the key contribution of mdma-at compared to an intensive, similarly somatic, and experimentally based, non-mdma treatment.

Eligibility criteria:
inclusion criteria: * 1. were assigned male sex at birth and currently identify as a male (e.g. are not transgender nor taking hormone replacement therapy) 2. are veterans of the israeli military 3. are at least 18 years old. 4. are fluent in speaking and reading hebrew 5. are able to swallow pills. 6. agree to have eeg (three times) and salivary monitoring (during experimental sessions) at multiple occasions throughout the study. 7. agree to have study visits recorded, including experimental sessions, independent rater assessments, and non-drug therapy sessions. 8. must provide a contact (relative, spouse, close friend or other support person) who is willing and able to be reached by the investigators in the event of a participant becoming unwell or unreachable. 8. must agree to inform the investigators within 48 hours of any medical conditions and procedures. 9. agree to the following lifestyle modifications: comply with requirements for fasting and refraining from certain medications prior to experimental sessions, not enroll in any other interventional clinical trials during the duration of the study, remain overnight at the study site after each experimental session and be driven home after, and commit to medication dosing, therapy, and study procedures. medical history 10. at screening, meet diagnostic criteria (diagnostic statisticians manual, 5th version, dsm-5) for current military-based ptsd with a symptom duration of 6 months or longer with a history of at least one attempt at psychiatric or psychological treatment. 11. at screening, have a pcl-5 total score of 33 or greater and at screening/baseline a confirmed diagnosis of ptsd per caps-5 and a total severity score of 28 or greater. 12. have a body weight of at least 45 kilograms. participants with a body weight of 45 to 48 kg must also have a body mass index (bmi) within the range of 18 to 30 kg/m2. 13. capable of giving signed informed consent. exclusion criteria: - medical conditions 1. alanine transaminase (alt) \[or aspartate transaminase (ast)\]higher than 2 x upper limit of normal (uln). 2. total bilirubin higher than 1.5 x uln (isolated bilirubin higher than; 1.5 x uln is acceptable if total bilirubin is fractionated and direct bilirubin less than; 35%). 3. current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis. • note: stable chronic liver disease (including gilbert's syndrome, asymptomatic gallstones, and chronic stable hepatitis b (e.g., the presence of hepatitis b surface antigen or positive hepatitis c antibody test result without evidence of active infection at screening or within 3 months prior to starting study intervention) is acceptable if the participant otherwise meets entry criteria. 4. have a recent history of clinically significant hyponatremia or hyperthermia. 5. have a marked baseline qtcf (qt interval corrected for heart rate ) interval higher than 450 ms demonstrated on repeated ecg (electrocardiogram) assessments. participants whose qtcf exceeds this value during screening may be initially enrolled if a pre-study concomitant medication is suspected to be prolonging the qt-interval. ecgs should be repeated after initial enrollment and tapering off the pre-study concomitant medication to ensure the participant meets eligibility criteria prior to enrolment confirmation and to imp dosing. • note: the qtcf is the qt interval corrected for heart rate according to fridericia's formula. it is either machine-read or manually over-read. 6. have a history of any medical condition that could make receiving a sympathomimetic drug harmful because of increases in blood pressure and heart rate. this includes, but is not limited to, a history of myocardial infarction, cerebrovascular accident, heart failure, severe coronary artery disease, or aneurysm. * participants with other mild, stable chronic medical problems may be enrolled if the study clinician and sponsor investigator (s-i) agree the condition would not significantly increase the risk of mdma administration or be likely to produce significant symptoms during the study that could interfere with study participation or be confused with side effects of mdma. * examples of stable medical conditions that could be allowed include but are not limited to human immunodeficiency virus (hiv) infection, gastroesophageal reflux disease (gerd), hypothyroidism (if taking adequate and stable thyroid replacement medication), glaucoma (if approval for study participation is received from an ophthalmologist). any medical disorder judged by the investigator to significantly increase the risk of harm from mdma exposure by any mechanism would require exclusion. 7. have a diagnosis of uncontrolled hypertension, defined as repeated blood pressure readings of ≥140 mmhg systolic or ≥90 mmhg diastolic. the diagnosis may be confirmed by repeated clinic measurements or home blood pressure monitoring if clinically indicated. • participants with well-controlled hypertension that has been successfully treated with anti-hypertensive medicines may be enrolled if they pass a risk assessment and potentially additional screening to rule out underlying cardiovascular disease. 8. have a history of ventricular arrhythmia at any time, other than occasional premature ventricular contractions (pvcs) in the absence of ischemic heart disease. 9. have wolff-parkinson-white syndrome or any other accessory pathway that has not been successfully eliminated by ablation. 10. have a history of arrhythmia, other than premature atrial contractions (pacs) or occasional pvcs in the absence of ischemic heart disease, within 12 months of screening. • participants with a history of atrial fibrillation, atrial tachycardia, atrial flutter or paroxysmal supraventricular tachycardia or any other arrhythmia associated with a bypass tract may be enrolled only if they have been successfully treated with ablation and have not had recurrent arrhythmia for at least one year off all antiarrhythmic drugs, as confirmed by a cardiologist. 11. have a history of additional risk factors for torsade de pointes (e.g., heart failure, hypokalemia, family history of long qt syndrome). psychiatric conditions (for mdma-at and somatic-based arms) 12. have engaged in a new form of psychiatric or mental health care within 12 weeks of enrollment, including electroconvulsive therapy (ect), and ketamine-assisted therapy. 13. are likely, in the investigator's opinion and via observation during the preparatory period, to be re-exposed to their index trauma or other significant trauma during the study. 14. have a current moderate (not in early remission in the 3 months prior to enrollment and meets at least 5 of 11 diagnostic criteria per dsm-5) or severe alcohol or cannabis use disorder within the 12 months prior to enrollment (meets at least 6 of 11 diagnostic criteria per dsm-5). • may have current mild alcohol or cannabis use disorder (meets 3 of 11 diagnostic criteria per dsm-5) or moderate alcohol or cannabis use disorder in early remission for the 3 months prior to enrollment (meets 4 or 5 of 11 diagnostic criteria per dsm-5). 15. have an active illicit drug (other than cannabis) or prescription drug substance use disorder at any severity within 12 months prior to enrollment. 16. any participant presenting current serious suicide risk, as determined through psychiatric interview, responses to columbia suicide severity rating scale (c-ssrs), and clinical judgment of the investigator will be excluded; however, history of suicide attempts is not an exclusion. any participant who is likely to require hospitalization related to suicidal ideation and behavior, in the judgment of the investigator, will not be enrolled. any participant presenting with the following on the baseline/screening c-ssrs will be excluded: * suicidal ideation score of 4 or greater within the last month of the assessment at a frequency of once a week or more. * suicidal ideation score of 5 within the last 6 months of the assessment. * any suicidal behavior, including suicide attempts or preparatory acts, within the last 6 months of the assessment. participants with non-suicidal self-injurious behavior may be included if approved by the study clinician. prior/concomitant therapy 17. unable or unwilling to safely taper-off prohibited psychiatric medication with exceptions described in section on concomitant medications in study protocol or require use of prohibited medications during experimental sessions. 18. require use of concomitant medications that could prolong the qt interval during experimental sessions. 19. have used ecstasy (unregulated material represented as containing mdma) more than 10 times within the last 10 years, or at least once within 6 months of the first experimental session. prior/concurrent clinical study experience 20. current enrollment in any other clinical study involving an investigational study treatment or any other type of medical research, unless approved by the study clinician. diagnostic assessments 21. have current personality disorders assessed via psychiatric assessment (by consultant psychiatrist). 22. have a current eating disorder with compensatory behaviors 23. have current major depressive disorder with psychotic features 24. have a history of, or a current primary psychotic disorder, bipolar affective disorder type 1 or dissociative identity disorder. other exclusions 25. sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the sponsor-investigator or study clinician, contraindicates participation in the study. 26. are currently engaged in compensation litigation whereby financial gain would be achieved from prolonged symptoms of ptsd or any other psychiatric disorders. 27. lack social support or lack a stable living situation. 28. previous participation in a maps-sponsored mdma clinical trial. 29. employees (and their immediate family members) of maps, maps public benefit corporation, or maps europe b.v; or individuals in a personal relationship with the site investigator. 30. have any current problem which, in the opinion of the sponsor-investigator or study clinician, might interfere with study participation. security criteria the current study dealing with intensive treatment of military veterans suffering from ptsd, requires an environment of physical and emotional security for the patients. safety is critical in the success of the treatment. since october 7, 2023, we have been in a continuous state of war, which we do not know when it will end. therefore, we are required at this time to define what security is as a criterion for conducting research at this time, and in relation to the normative reality in the world and in the state of israel in particular. therefore: 1. the research will be carried out in jerusalem and long sessions will not take place when there is a high risk of rocket attack or sirens during the previous day/night. 2. the participants in the study will be military veterans who do not participate or have taken an operational part in the war in the three months prior to the start of their participation in the study. 3. the participants in the study do not have first degree relatives or a partner who are actively serving in a war zone at the time of their participation in the study. 4. the participants live in a permanent and safe place and are not expected to change their place of residence during their participation in the study.

Keywords: mdma ptsd moral injury oxytocin veterans hyperarousal